ICCG Neocent

Neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer

Disease site: Breast cancer

Treatment Modality: Combination therapy

Status: Closed

Trial details

Neocent is a multi-centre randomised, parallel group, comparative phase III neo-adjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with strongly ER positive primary breast cancer in whom it is felt cytoreductive pre-operative systemic therapy is indicated.

Neoadjuvant chemotherapy is a standard of care for down-staging of breast cancer pre-operatively. However, aromatase inhibitors (AIs) also have activity in this setting in postmenopausal women with oestrogen receptor (ER) positive breast cancer (Eiermann et al., 2001). In strongly ER positive breast cancer, chemotherapy efficacy is reduced, whereas, the efficacy of AIs appears greatest and it is unclear which treatment response is more efficacious.

Overall, 70% of breast cancers are ER positive, and in postmenopausal women 85% of these are strongly ER positive (Ellis M, 2003). This study will help clarify optimal treatment for this patient group.

The study is divided into two phases, a pilot phase and a main efficacy phase. The aim of the pilot study is to assess the feasibility of patient recruitment and tissue collection for a subsequent ‘main study’. The pilot study requires 20 patients per treatment group.

This is an International Collaborative Cancer Group trial (ICCG) (C/21/07).

Chief Investigator: Professor R. C. Coombes, Imperial College, London

ICR-CTSU Scientific Lead: Professor Judith Bliss

Trial management contact: Please see the ICCG Necent webpage

ISRCTN: 77234840

Sponsor: Imperial College London

Funding: Cancer Research UK (C37/A9356), Novartis

Further Information

Further information on the Neocent trial may be found on the ICCG Necent webpage

breast cancer cell
Major trial shows prolonged benefit of olaparib in early-stage inherited breast cancer

12/12/24

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
See full story
Breast cancer cell spheroid blue and purple
New understanding of aggressive form of breast cancer paves the way for tests and treatments

10/12/24

Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.
See full story